CSL shares are in the red for 2024. Are they a buy?

Meanwhile, the broader market has extended to new highs this year.

| More on:
Male doctor in a lab coat working at laptop looking serious.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares have faced a tough year. Whilst the broader market has extended to new highs in 2024, shares in the biotech giant are less than 1% in the red.

They are currently swapping hands at $285.30 apiece, down from highs of more than $312 back in July.

But despite the recent dip, many analysts believe CSL shares are undervalued and present a solid long-term investment opportunity. Let's see what the experts say.

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALL1 Nov 20235 Nov 2024Zoom ▾Nov '23Jan '24Mar '24May '24Jul '24Sep '24Nov '24Jan '24Jan '24Apr '24Apr '24Jul '24Jul '24Oct '24Oct '24www.fool.com.au

What's driving CSL shares down?

Several factors have weighed on CSL shares this year. One of the primary concerns is related to the company's acquisition of Swiss company Vifor Pharma, which specialises in iron deficiency treatments.

Despite the initial optimism around this purchase, Vifor's performance hasn't met expectations. This has impacted CSL's earnings and contributed to the downtrend since full-year earnings were released in August.

Additionally, CSL recently faced regulatory hurdles with some of its product trials. US regulators flagged manufacturing concerns over a new treatment in CSL's pipeline.

The company has subsequently pulled studies on three therapies due to regulatory and timing issues.

Shareholders were so unhappy with CSL's performance this year that a quarter voted against the CEO's proposed remuneration package at the AGM.

Brokers are bullish

Sifting through the smoke and looking more long-term, brokers are generally bullish on CSL shares. According to CommSec, the stock is rated a buy from consensus.

Analysts at Citi, Bell Potter, and Morgans all maintain a positive outlook on CSL. They highlight the company's core CSL Behring business as a key growth driver.

Citi retained its buy rating and a $345.00 price target on the stock, citing strong growth in CSL's immunoglobulin and albumin sales.

Meanwhile, Bell Potter echoes this sentiment. It sees CSL's double-digit earnings growth potential as attractive despite near-term challenges.

With the shares currently trading at a discount to historical averages, the broker argues now might be an ideal entry point.

Morgans, on the other hand, values the business at $330.75 per share. It, too, says CSL shares are a buy and has a strong view of the Behring business.

There are no sell ratings on the stock either, according to CommSec data.

Foolish takeout

Despite the challenges, CSL shares are widely regarded as undervalued by experts. The market has been swift in selling the stock since August.

But for those who are long-term oriented, the company's market position and earnings growth forecasts remain on check.

In the last 12 months, the stock is up more than 15%.

Should you invest $1,000 in CSL right now?

Before you buy CSL shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Woman with headphones on relaxing and looking at her phone happily.
Healthcare Shares

Everything you need to know about the latest CSL dividend

CSL's latest dividend should be turning investors' heads...

Read more »

thoughtful investor sitting at computer
Healthcare Shares

What are brokers saying about CSL shares after the selloff?

The biotech giant's shares hit a 52-week low yesterday. Is this a buying opportunity?

Read more »

A man looking at his laptop and thinking.
Earnings Results

CSL shares push higher despite 'mixed result with headline misses'

There were positives and negatives in the company's first half performance.

Read more »

Scientists working in the laboratory and examining results.
Earnings Results

CSL share price on watch amid $2.1b half year profit and dividend hike

Let's see how this biotech giant performed during the first half of FY 2025.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 300 healthcare stock just rocketed 20% on BIG earnings growth

Investors are piling into the ASX 300 healthcare stock on Monday. But why?

Read more »

Health professional putting on gloves.
Earnings Results

Why this ASX 200 share is soaring in Monday's sinking market

The ASX 200 share is shrugging off the broader market fall today to rocket higher. But why?

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Why is the Sigma share price soaring 6%?

Sigma has upgraded its FY25 guidance ahead of the anticipated Chemist Warehouse merger completion.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Which ASX 200 healthcare share will pay the best dividend yield in 2025?

Earnings season is underway and dividend announcements are on investors' minds.

Read more »